<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>meta-epidemiology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/meta-epidemiology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Oct 2026 19:50:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>meta-epidemiology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Real-World Breast Cancer Studies Report Higher Response Rates Than Randomized Trials</title>
		<link>https://bioengineer.org/real-world-breast-cancer-studies-report-higher-response-rates-than-randomized-trials/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 24 Oct 2026 19:50:06 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[advanced breast cancer]]></category>
		<category><![CDATA[adverse events]]></category>
		<category><![CDATA[BMC Cancer]]></category>
		<category><![CDATA[CDK4/6 inhibitors]]></category>
		<category><![CDATA[endocrine therapy]]></category>
		<category><![CDATA[HER2-negative]]></category>
		<category><![CDATA[hormone receptor-positive]]></category>
		<category><![CDATA[meta-epidemiology]]></category>
		<category><![CDATA[objective response rate]]></category>
		<category><![CDATA[palbociclib]]></category>
		<category><![CDATA[randomized trials]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=452243</guid>

					<description><![CDATA[A meta-epidemiological analysis of 86 studies found that real-world cohorts of patients taking CDK4/6 inhibitors for hormone receptor-positive, HER2-negative advanced breast cancer reported higher objective response rates and lower symptom-based adverse events than randomized trial arms, while dose reductions were more frequent in routine practice.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">452243</post-id>	</item>
	</channel>
</rss>
